Rigel Pharmaceuticals heads into its third-quarter report with the stock near its highs and a new story to prove. Last quarter, management reframed the company around Vepinu, a breast cancer drug licensed from Arvinas and Pfizer that became commercially available in mid-August, ahead of schedule. Management described it as potentially Rigel's largest revenue producer. The upcoming release, due after the close on November 5, will offer the first real look at roughly six weeks of launch activity. That evidence arrives just as the legacy portfolio is losing the tailwind that powered 2025.
The Street is not asking for much on the top line. Consensus calls for revenue of $78.3 million, up 12.7% from $69.5 million a year ago but essentially flat with the $78.7 million reported last quarter. Earnings are expected to come in at $0.87 a share, down about 40% from $1.46 in the year-ago period. That decline reflects a richer prior-year comparison and the heavier cost structure that comes with launching and supporting a new oncology asset. Notably, the full-year consensus of about $280.6 million sits below the low end of management's recently raised $285 million to $295 million range. Analysts are either skeptical of the raise or slow to adjust. Either way, the bar looks beatable if the base business holds.
The composition of revenue matters more than the headline. Management held net product sales guidance at $255 million to $265 million and explicitly excluded any Vepinu contribution. The guidance lift came instead from contract revenue, now seen near $30 million versus $20 million to $25 million before. That means Vepinu sales are pure upside to the stated outlook, and any meaningful early uptake would argue that the range is conservative. On the other hand, a flat sequential quarter dominated by contract revenue would suggest the guidance raise was more accounting than momentum.
The core franchise also deserves scrutiny. Tavalis, still the cornerstone, posted $47.4 million last quarter, up 18%. ResLydia grew 27% to $8.9 million, though its growth rate has been easing for several quarters. Gavretto slipped into a modest decline at $10.7 million. Total product growth decelerated to 14% in the second quarter from 65% a year earlier, and management attributed much of 2025's surge to a one-time gross-to-net benefit that will not repeat. Steady Tavalis demand and continued double-digit ResLydia growth would validate the view that the base is decelerating gracefully rather than stalling. A further Gavretto slide or softer Tavalis pricing would challenge it.
The balance sheet is the other swing factor. Cash fell to $95.3 million after the $70 million Vepinu upfront payment, with $15 million in transition milestones and up to $40 million of development support still ahead. Investors should look for evidence that launch spending is disciplined and that the company can fund Vepinu without leaning on dilution. Commentary on the R289 lower-risk MDS data, still slated for year-end, will matter for the pipeline narrative.
Sentiment has warmed, though it remains on the bearish side, improving to a reading of -0.295 from -0.445 ahead of the last report. The stock has rallied 19.4% since then while the S&P 500 slipped, and at $50.74 it trades well above its 200-day average of $37.01. It also sits within about 1% of its post-earnings high of $51.36, effectively testing a breakout. That leaves less room for ambiguity. The report will be judged on whether early Vepinu traction and a stable core business together show that Rigel's transformation into a diversified oncology and hematology company is real, rather than a guidance raise built mainly on contract revenue.